Skip to content
WorldBrand.AI

Ascletis Pharma Inc.

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    Viking alleges trade secret theft; US ITC finds Section 337 violation and recommends ban

    US-based Viking Therapeutics alleged that Ascletis Pharma founder Wu Jinzi and others used its VK2809 confidential information to develop pipelines including ASC41/ASC43F. The US International Trade Commission (ITC) finally ruled that imports of Ascletis-related products violate Section 337 and recommended a seven-year ban; the company accrued fines, and civil litigation is still ongoing; previously the company's stock had plunged about 95% from its high. ITC ban; litigation ongoing.

    Source